Diana Wüthrich, Michele Zeverino, Jean Bourhis, François Bochud, Raphaël Moeckli
PURPOSE: In inverse radiotherapy treatment planning, the Pareto front is the set of optimal solutions to the multi-criteria problem of adequately irradiating the planning target volume (PTV) while reducing dose to organs at risk (OAR). The Pareto front depends on the chosen optimisation parameters whose influence (clinically relevant versus not clinically relevant) is investigated in this paper. METHODS: Thirty-one prostate cancer patients treated at our clinic were randomly selected...
September 25, 2023: Physica Medica: PM
Samantha Tam, Christine Neslund-Dudas, Amy M Barrett, Lauren C J Barrow, Ilona Fridman, Alan C Kinlaw, Praveen Puviindran, Trevor J Royce, Angela B Smith, Jacob N Stein, William A Wood, Jennifer Elston Lafata
BACKGROUND: With the COVID-19 pandemic came rapid uptake in virtual oncology care. During this, sociodemographic inequities in access to virtual visits (VVs) have become apparent. To better understand these issues, we conducted a qualitative study to describe the perceived usability and acceptability of VVs among Black adults diagnosed with cancer. METHODS: Adults who self-identified as Black and had a diagnosis of prostate, multiple myeloma, or head and neck cancer were recruited from 2 academic medical centers, and their community affiliates to participate in a semi-structured interview, regardless of prior VV experience...
September 26, 2023: Oncologist
Phuong The Nguyen, Megumi Hori, Tomohiro Matsuda, Kota Katanoda
BACKGROUND: We provide comprehensive sex-stratified projections of cancer prevalence for 22 cancer sites in Japan from 2020 to 2050. METHODS: Using a scenario-based approach, we projected cancer prevalence by combining projected incidence cases and survival probabilities. Age-specific incidences were forecasted using age-period-cohort models, while survival rates were estimated using a period-analysis approach and multiple parametric survival models. To understand changes in cancer prevalence, decomposition analysis was conducted, assessing the contributions of incidence, survival, and population demographics...
September 27, 2023: Cancer Epidemiology, Biomarkers & Prevention
Abtin Doroudinia, Satyanarayana Chekuri
18F-FDG PET/CT scan is a well-known modality to assess distant metastases and treatment response in the patients with primary colon cancer. We are presenting an interesting case of 68Ga-PSMA-avid liver metastases in a 74-year-old man with colon cancer and recently diagnosed prostate cancer. The liver metastases were positive on initial FDG PET but lost FDG avidity on subsequent posttreatment FDG PET scans. Biopsy from the PSMA-avid liver lesions confirmed metastasis from colon origin. PSMA is expressed in various forms of tumor neovasculature other than prostate cancer with potential new applications as a theranostic agent in the future...
September 19, 2023: Clinical Nuclear Medicine
Yuliya V Ryabova, Ilzira A Minigalieva, Marina P Sutunkova, Svetlana V Klinova, Alexandra K Tsaplina, Irene E Valamina, Ekaterina M Petrunina, Aristides M Tsatsakis, Charalampos Mamoulakis, Kostas Stylianou, Sergey V Kuzmin, Larisa I Privalova, Boris A Katsnelson
Chronic diseases of the urogenital tract, such as bladder cancer, prostate cancer, reproductive disorders, and nephropathies, can develop under the effects of chemical hazards in the working environment. In this respect, nanosized particles generated as by-products in many industrial processes seem to be particularly dangerous to organs such as the testes and the kidneys. Nephrotoxicity of element oxide particles has been studied in animal experiments with repeated intraperitoneal injections of Al2 O3 , TiO2 , SiO2 , PbO, CdO, CuO, and SeO nanoparticles (NPs) in total doses ranging from 4...
September 19, 2023: Toxics
Serban Negoita, Huann-Sheng Chen, Pamela V Sanchez, Recinda L Sherman, S Jane Henley, Rebecca L Siegel, Hyuna Sung, Susan Scott, Vicki B Benard, Betsy A Kohler, Ahmedin Jemal, Kathleen A Cronin
BACKGROUND: With access to cancer care services limited because of coronavirus disease 2019 control measures, cancer diagnosis and treatment have been delayed. The authors explored changes in the counts of US incident cases by cancer type, age, sex, race, and disease stage in 2020. METHODS: Data were extracted from selected US population-based cancer registries for diagnosis years 2015-2020 using first-submission data from the North American Association of Central Cancer Registries...
September 27, 2023: Cancer
Nelson Peixoto, Elisabeth Grobet-Jeandin, Fabian Schoofs, Olivier Windisch, Christophe Iselin, Daniel Benamran
PURPOSE: Patients who undergo robot-assisted laparoscopic radical prostatectomy (RARP) may present concurrent or secondary inguinal hernia (IH). Surgical repair of IH simultaneously with RARP has been reported. We aimed to assess the long-term efficacy of concurrent prosthetic IH repair with RARP. METHODS: Data for consecutive patients undergoing concurrent IH repair with RARP for localized prostate cancer at our institution between 2006 and 2017 were retrospectively analysed...
September 27, 2023: World Journal of Urology
Fabio Zattoni, Leonor J Paulino Pereira, Giancarlo Marra, Massimo Valerio, Jonathan Olivier, Ignacio Puche-Sanz, Pawel Rajwa, Martina Maggi, Riccardo Campi, Daniele Amparore, Sabrina De Cillis, Zhuang Junlong, Hongqian Guo, Giulia La Bombarda, Andrea Fuschi, Alessandro Veccia, Francesco Ditonno, Alessandro Marquis, Francesco Barletta, Riccardo Leni, Sergio Serni, Veeru Kasivisvanathan, Alessandro Antonelli, Fabrizio Dal Moro, Juan Gomez Rivas, Roderick C N van den Bergh, Alberto Briganti, Giorgio Gandaglia, Giacomo Novara
OBJECTIVE: To evaluate the proportions of detected prostate cancer (PCa) and clinically significant PCa (csPCa), as well as identify clinical predictors of PCa, in patients with PI-RADS >  = 3 lesion at mpMRI and initial negative targeted and systematic biopsy (initial biopsy) who underwent a second MRI and a re-biopsy. METHODS: A total of 290 patients from 10 tertiary referral centers were included. The primary outcome measures were the presence of PCa and csPCa at re-biopsy...
September 27, 2023: World Journal of Urology
Gabriela Ilie, Cody MacDonald, Hal Richman, Ricardo Rendon, Ross Mason, Alexandra Nuyens, Greg Bailly, David Bell, Nikhilesh Patil, David Bowes, Emmi Champion, Derek Wilke, Lia Massoeurs, Nada Hassan, Robert David Harold Rutledge
A 28-day Prostate Cancer-Patient Empowerment Program (PC-PEP) developed through patient engagement was successful at promoting mental and physical health. Thirty prostate cancer patients from Halifax, Canada participated in the 28-day PC-PEP intervention in early 2019. PC-PEP encompassed daily patient education and empowerment videos, prescribed physical activities (including pelvic floor exercises), a mostly plant-based diet, stress reduction techniques, intimacy education, social connection, and support. Quantitative exit surveys and semi-structured interviews (conducted in focus groups of ten) were used to assess perceived factors that facilitated or impeded adherence to the program...
September 21, 2023: Current Oncology
Safiya Karim, Jennifer Lowther, Gabriel Gyulay, Dylan O'Sullivan, Christopher J D Wallis, Steven M Yip, Darren R Brenner, Devon J Boyne, Winson Y Cheung
INTRODUCTION: Over the past decade, the treatment of metastatic castration-sensitive prostate cancer (mCSPC) has changed significantly. Current guidelines suggest the use of androgen deprivation therapy (ADT) plus an additional systemic therapy, regardless of disease burden and risk, based on phase 1 evidence showing improved overall survival. We sought to describe treatment patterns of patients with mCSPC in the province of Alberta. METHODS: This was a retrospective, population-based, cohort study of male patients aged ≥18 with mCSPC at the time of diagnosis and who initiated ADT between 1 January 2016 and 31 December 2020...
September 1, 2023: Current Oncology
Kazuyuki Numakura, Mizuki Kobayashi, Yumina Muto, Hiromi Sato, Yuya Sekine, Ryuta Sobu, Yu Aoyama, Yoshiko Takahashi, Syuhei Okada, Hajime Sasagawa, Shintaro Narita, Satoshi Kumagai, Yuki Wada, Naoko Mori, Tomonori Habuchi
A recent approach to radiotherapy for prostate cancer is the administration of high doses of radiation to the prostate while minimizing the risk of side effects. Thus, image-guided radiotherapy utilizes advanced imaging techniques and is a feasible strategy for increasing the radiation dose. New radioactive particles are another approach to achieving high doses and safe procedures. Prostate brachytherapy is currently considered as a combination therapy. Spacers are useful to protect adjacent organs, specifically the rectum, from excessive radiation exposure...
September 1, 2023: Current Oncology
Alessandro Sciarra, Valerio Santarelli, Lorenzo Santodirocco, Marco Frisenda, Stefano Salciccia, Paolo Casale, Flavio Forte, Gianna Mariotti, Martina Moriconi, Susanna Cattarino, Beatrice Sciarra, Giulio Bevilacqua, Alessandro Gentilucci
The increasing diffusion of genetic analysis regarding the pathogenetic variants (PVs) of genes involved in DNA Damage Repair (DDR) mechanisms and the development of Poly ADP ribose polymerase (PARP) inhibitors (PARPis) led to the first valid precision medicine option tailored toward metastatic prostate cancer (mPC). The concept of anticipation in the systemic treatment of mPC was initially adopted for androgen receptor signaling inhibitors (ARSIs) to describe the expansion of their indications, from the setting of the late-stage second-line treatment of metastatic castration-resistant prostate cancer (mCRPC) to first-line therapy in selected cases...
August 30, 2023: Current Oncology
Maria-Josep Carreras, Elena Tomás-Guillén, Anna Farriols, Berta Renedo-Miró, Carolina Valdivia, Jana Vidal, Cristina Saura, Joan Carles, Enriqueta Felip, Maria-Queralt Gorgas, Josep Tabernero, Josep Monterde
BACKGROUND: Cancer is one of the leading causes of morbidity and mortality in the world. Its growing incidence and prevalence, as well as the advances in diagnostic and treatment tools, motivate an open debate about the economic burden it may place on health systems and have raised concerns about access to this technological innovation. There is a lack of information on the detailed costs of pharmacological treatment of cancer in our health setting. In this context, it is necessary to know the use of drugs in cancer treatment in conditions of real clinical practice...
August 30, 2023: Current Oncology
Laura Burge, Gabriela Ilie, Cody MacDonald, Hayley Riel, Rob David Harold Rutledge
Prostate cancer (PCa) survivors often experience post-treatment challenges that impact their well-being and mental health. The Prostate Cancer Patient Empowerment Program (PC-PEP) aims to address these issues through a comprehensive intervention, involving daily meditation/breathing exercises, physical activity, pelvic floor exercises, emotional connection strategies, and peer support. This study presents a secondary analysis of a Phase 2 feasibility study that evaluated the effects of a 28-day PC-PEP intervention on stress reduction...
August 29, 2023: Current Oncology
Andrea Vavassori, Giovanni Mauri, Giovanni Carlo Mazzola, Federico Mastroleo, Guido Bonomo, Stefano Durante, Dario Zerini, Giulia Marvaso, Giulia Corrao, Elettra Dorotea Ferrari, Elena Rondi, Sabrina Vigorito, Federica Cattani, Franco Orsi, Barbara Alicja Jereczek-Fossa
In this technical development report, we present the strategic placement of fiducial markers within the prostate under the guidance of computed tomography (CT) and electromagnetic navigation (EMN) for the delivery of ultra-hypofractionated cyberknife (CK) therapy in a patient with localized prostate cancer (PCa) who had previously undergone chemo-radiotherapy for rectal cancer and subsequent abdominoperineal resection due to local recurrence. The patient was positioned in a prone position with a pillow under the pelvis to facilitate access, and an electromagnetic fiducial marker was placed on the patient's skin to establish a stable position...
August 28, 2023: Current Oncology
Mandisa Mbeje, Jeyalakshmi Kandhavelu, Clement Penny, Mmamoletla Kgoebane-Maseko, Zodwa Dlamini, Rahaba Marima
Prostate cancer (PCa) is the leading cancer in men globally. The association between PCa and long non-coding RNAs (lncRNAs) has been reported. Aberrantly expressed lncRNAs have been documented in each of the cancer "hallmarks". Androgen signaling plays an important role in PCa progression. This study aimed to profile the aberrantly expressed lncRNAs in androgen-dependent (LNCaP) PCa compared to androgen-independent (PC-3) PCa cells. This was achieved by using a 384-well plate of PCa lncRNA gene panel. Differential expression of ±2 up or downregulation was determined using the CFX Maestro software v2...
September 1, 2023: Current Issues in Molecular Biology
Gisella Bermúdez, Camila Bernal, Andrea Otalora, Paula Sanchez, Gino Nardocci, Alejandra Cañas, Liliana Lopez-Kleine, Martín Montecino, Adriana Rojas
BACKGROUND: Lung cancer is the leading cause of cancer death worldwide. It has been reported that genetic and epigenetic factors play a crucial role in the onset and evolution of lung cancer. Previous reports have shown that essential transcription factors in embryonic development contribute to this pathology. Runt-related transcription factor (RUNX) proteins belong to a family of master regulators of embryonic developmental programs. Specifically, RUNX2 is the master transcription factor (TF) of osteoblastic differentiation, and it can be involved in pathological conditions such as prostate, thyroid, and lung cancer by regulating apoptosis and mesenchymal-epithelial transition processes...
August 24, 2023: Current Issues in Molecular Biology
Joshua Cabral, Sarah K Holt, Samuel L Washington, Erin Dwyer, Jenney R Lee, Erika M Wolff, John L Gore, Yaw A Nyame
INTRODUCTION: Patients with mental health disorders are at risk for receiving inequitable cancer treatment, likely resulting from various structural, social, and health-related factors. This study aims to assess the relationship between mental health disorders and the use of definitive treatment in a population-based cohort of those with localized, clinically significant prostate cancer. METHODS: We conducted a cohort study analysis in SEER (Surveillance, Epidemiology, and End Results)-Medicare (2004-2015)...
September 26, 2023: Urology Practice
Benjamin Pockros, Kristian Stensland, Vahakn Shahinian
No abstract text is available yet for this article.
September 26, 2023: Urology Practice
Gianluca Ferini, Stefano Pergolizzi
No abstract text is available yet for this article.
November 2023: Clinical and Translational Radiation Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.